La porpora trombocitopenica idiopatica: Una stima del costo della malattia in Italia

Translated title of the contribution: Immune thrombocytopenic purpura: An evaluation of its economic burden in Italy

C. Lucioni, S. Mazzi, S. Chiroli, F. Ciceri, R. Santi, M. Ruggeri, R. Stasi

Research output: Contribution to journalArticlepeer-review


Introduction: Immune thrombocytopenic purpura (ITP), a rare autoimmune disorder characterized by formation of anti-platelet antibodies, causes an increased medical resource utilization associated with bleeding events, hospitalization, emergency medication. This study aimed at assessing the current clinical practice and resources used in the treatment of ITP in Italy, and at estimating the total cost of ITP-related care. Materials and methods: The study is a multi-centre, retrospective cohort evaluation, focused on adult patients treated for chronic ITP in Italy, conducted from the economic perspective of the National Health Service (NHS). Clinical records available in the participating Centres and satisfying the eligibility criteria were sequentially scrutinized (each record was reviewed back to the original date of diagnosis or as far back as archives permitted) and abstracted to Case Report Forms for data processing. Drug costs were evaluated applying the respective retail prices. For lab tests, current tariffs were used. Hospitalisation costs were based on DRG tariffs the NHS reimburses to hospitals. All costs are referred to 2008. Results: Patients scrutinized were 131. Mean age at enrolment was 57 years and males were 36%. The mean platelet count at ITP diagnosis was 39,400/μL and standard deviation 35,700/μL. For 24% of patients, ITP was diagnosed in the course of a hospitalisation (i.e. unduly late, only when severe symptoms had occurred). Among patients after splenectomy, almost half of the platelet counts anyhow remained below 50,000μ L (the clinically accepted safety threshold). Total medical costs for ITP follow-up amount to a mean value of €3,293 per patient per year. Of such amount, 56% is due to medications and 38% to hospitalisations. Lab tests and specialist visits account for the remaining 6%. Almost all cost for medications (97%) is due to IVIg/anti-D treatments. Conclusions: Based on a conservative assumption of 1,200 adult patients with chronic ITP in Italy, the cost of the disease for NHS would amount to almost €4m per year.

Translated title of the contributionImmune thrombocytopenic purpura: An evaluation of its economic burden in Italy
Original languageItalian
Pages (from-to)95-104
Number of pages10
JournalPharmacoEconomics - Italian Research Articles
Issue number2
Publication statusPublished - 2009

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Health Policy


Dive into the research topics of 'Immune thrombocytopenic purpura: An evaluation of its economic burden in Italy'. Together they form a unique fingerprint.

Cite this